Lack of osteopontin dissociates NASH‐fibrosis severity from overall survival and HCC malignant transformation in NAFLD, and is therefore a putative therapeutic target only for advanced chronic liver disease. This evidence concerns the gene SPP1 and metabolic dysfunction-associated steatohepatitis.